Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4 studies found for:    16549646 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Novel Treatment of Intermittent Claudication in Patients With Peripheral Arterial Disease Using Danshen Gegen (D&G) Capsule
Conditions: Peripheral Arterial Disease;   Intermittent Claudication
Interventions: Drug: Danshen Gegen Capsule;   Drug: Placebo
2 Recruiting Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities
Condition: Peripheral Arterial Disease
Interventions: Drug: 1 month daily 75 mg plavix;   Drug: 12 months daily 75 mg plavix;   Drug: 12 months daily 75-100 mg aspirin;   Drug: 1 month daily 75-100 mg aspirin
3 Active, not recruiting Patients With Intermittent Claudication Injected With ALDH Bright Cells
Conditions: Peripheral Artery Disease;   Intermittent Claudication
Interventions: Biological: ALD-301;   Biological: Placebo (vehicle)
4 Completed Intensive Rehabilitation in Peripheral Arterial Disease With Claudication: Effects of a Treadmill Training With Active Recovery
Conditions: Peripheral Arterial Disease;   Claudication
Interventions: Procedure: experimental rehabilitation program;   Procedure: conventional rehabilitation program

Indicates status has not been verified in more than two years